June 22, 2018

Prof Sam Janes joins Optellum Medical Advisory Board

Prof Sam Janes MD FRCP

Optellum welcomes an internationally renowned physician and scientist in early lung cancer diagnosis and treatment,  Dr. Sam Janes MD, to join its Medical Advisory Board.

Prof. Janes works as a respiratory consultant at UCLH with a particular interest in Lung Cancer, mesothelioma, interventional and diagnostic bronchoscopy and early lung cancer detection. He is Head of Respiratory Research Department at UCL, director of the Lung Cancer Board for London Cancer, lead for Pulmonary at the International Society of Cellular Therapies and Vice-Chair of the National ‘Clinical Expert Group’ on Lung Cancer.

Prof. Janes’s research focuses on genetic and cellular changes in lung cancer pathogenesis. The ambition is that from this knowledge he can develop therapies detecting and targeting early lung cancers and thereby dramatically improve outcomes.

Prof. Janes runs the UCLH lung cancer team. He has developed a new endobronchial ultrasound service and performs all the invasive bronchoscopic techniques. He is running several clinical trials aiming to improve the patient journey of diagnosis and staging of lung cancers.

Prof. Janes joins a global team of physicians that help Optellum redefine early intervention in lung cancer, including

  • Prof. Lutz Freitag MD,  Interventional Pulmonologist, Hirslanden Klinik St. Anna & medical device inventor (100+ patents in pulmonary medicine)
  • Prof. Fergus Gleeson MD, Professor of Radiology,  University of Oxford  (co-author of British Thoracic Society pulmonary nodule & NICE lung cancer guidelines)
  • Prof. Pierre Massion MD,  Pulmonologist, Cornelius Vanderbilt Chair in Medicine, Ingram Professor of Cancer Research, Vanderbilt Medical Center (co-author NCCN lung cancer guidelines)
  • Prof. Reginald Munden MD, Chair of Radiology,  Wake Forrest Baptist Health (ACR guidelines, M.D. Anderson Cancer Centre PI in the US National Lung Screening Trial).
  • Prof. Matthijs Oudkerk MD, Chair of Radiology, University Medical Center Groningen (co-PI NELSON Study – Europe’s largest lung screening trial)

Recent posts

August 24, 2026 / News & Press, Partnerships
SimonMed Launches World’s First Seamlessly Integrated AI Lung Nodule Risk Assessment Workflow
SimonMed is creating the first fully automated AI-powered lung cancer risk assessment workflow deployed at enterprise scale, combining multiple FDA-cleared AI technologies into a...
Read more
August 13, 2026 / News & Press, Partnerships
Coreline Soft and Optellum announce intent to collaborate to advance AI...
Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform
Read more
June 15, 2026 / News & Press, Partnerships
Optellum Awarded NIHR Funding for Multi-Site NHS Pilot Study for Accelerated...
Optellum announced it has been awarded funding for a competitive programme, Invention for Innovation (i4i), focused on transformative and disruptive innovations to reduce waiting...
Read more
Optellum is trusted by industry & academic leaders
IntuitiveJohnson & JohnsonConcert AIGE HealthcareNHSUniversity of OxfordVanderbilt University Medical CenterAtrium HealthPenn MedicineUConn HealthJupiter Medical CenterGeorgia Cancer Center Augusta University
IntuitiveJohnson & JohnsonConcert AIGE HealthcareNHSUniversity of OxfordVanderbilt University Medical CenterAtrium HealthPenn MedicineUConn HealthJupiter Medical CenterGeorgia Cancer Center Augusta University
IntuitiveJohnson & JohnsonConcert AIGE HealthcareNHSUniversity of OxfordVanderbilt University Medical CenterAtrium HealthPenn MedicineUConn HealthJupiter Medical CenterGeorgia Cancer Center Augusta University
Certification
Redefining early intervention of lung disease starting with one of the deadliest, lung cancer
Contact us